Genome-wide association studies (GWASs) have identified more than 70 loci associated with type 2 diabetes (T2D), but for most, the underlying causal variants, associated genes, and functional mechanisms remain unknown. At a T2D-and fasting-proinsulin-associated locus on 11q13.4, we have identified a functional regulatory DNA variant, a candidate target gene, and a plausible underlying molecular mechanism. Fine mapping, conditional analyses, and exome array genotyping in 8,635 individuals from the Metabolic Syndrome in Men study confirmed a single major association signal between fasting proinsulin and noncoding variants (p ¼ 7.4 3 10 À50 ). Measurement of allele-specific mRNA levels in human pancreatic islet samples heterozygous for rs11603334 showed that the T2D-risk and proinsulin-decreasing allele (C) is associated with increased ARAP1 expression (p < 0.02). We evaluated four candidate functional SNPs for allelic effects on transcriptional activity by performing reporter assays in rodent pancreatic beta cell lines. The C allele of rs11603334, located near one of the ARAP1 promoters, exhibited 2-fold higher transcriptional activity than did the T allele (p < 0.0001); three other candidate SNPs showed no allelic differences. Electrophoretic mobility shift assays demonstrated decreased binding of pancreatic beta cell transcriptional regulators PAX6 and PAX4 to the rs11603334 C allele. Collectively, these data suggest that the T2D-risk allele of rs11603334 could abrogate binding of a complex containing PAX6 and PAX4 and thus lead to increased promoter activity and ARAP1 expression in human pancreatic islets. This work suggests that increased ARAP1 expression might contribute to T2D susceptibility at this GWAS locus.
Introduction
Genome-wide association studies (GWASs) have identified more than 70 loci associated with type 2 diabetes (T2D [MIM 125853]) [1] [2] [3] [4] [5] [6] [7] [8] [9] and ten loci associated with fasting proinsulin levels. 10, 11 A 11q13.4 locus near ARAP1 (MIM 606646), PDE2A (MIM 602658), STARD10, ATG16L2, and FCHSD2 is strongly associated with T2D (rs1552224, p ¼ 1.4 3 10 À22 ), 1 fasting proinsulin (rs11603334, p ¼ 3.2 3 10 À102 ), 10 and 32,33-split proinsulin (rs11603334, p ¼ 1.2 3 10 À25 ). 10 This locus is also nominally associated with the insulinogenic index (rs1552224, p ¼ 2 3 10 À6 ) and both insulin (p ¼ 0.001) and glucose (p ¼ 2 3 10 À5 ) levels at 30 min during an oral glucose tolerance test. 12 The clustering of multiple phenotypic associations related to proinsulin processing and insulin secretory response during an oral glucose challenge suggests that the affected target gene(s) might play a role in pancreatic beta cell function. Currently, the functional DNA variant(s), the affected gene(s), and the underlying molecular genetic mechanism(s) contributing to these associations are unknown.
SNPs rs1552224 and rs11603334 are in perfect linkage disequilibrium (LD) with each other (r 2 ¼ 1, 1000 Genomes European ancestry [EUR] ) and are located within the first exon and 5 0 UTR of ARAP1 RefSeq isoforms NM_015242.4 and NM_001135190.1 (rs1552224, þ305 nt from the transcription start site [TSS]; rs11603334, þ418 nt from the TSS) at 72.11 Mb (hg18, UCSC Genome Browser) on chromosome 11. A third ARAP1 RefSeq isoform, NM_001040118.2, is expressed from an alternative promoter and TSS located at 72.14 Mb. We designate the promoter at 72.11 Mb as P1 and the promoter at 72.14 Mb as P2.
We hypothesized that functional variant(s) at this locus are in high LD (r 2 R 0.8) with rs1552224 and rs11603334. None of the variants in high LD with these SNPs are within gene coding regions where they could alter protein function, suggesting that functional common SNP(s) at this locus might influence gene regulation. Genes within the LD region containing rs1552224 and rs11603334 have reported expression in human pancreas, islets, and flow-sorted beta cells; 1 however, islet expression of ATG16L2, FCHSD2, and PDE2A might not be above background. [13] [14] [15] None of these genes have been demonstrated to play roles in insulin processing or secretion. ARAP1 activates Arf and Rho GTPases, which regulate membrane trafficking and actin cytoskeleton reorganization. 16 STARD10 binds and transfers membrane phospholipids. 17 PDE2A is a cyclic nucleotide phosphodiesterase that degrades second messengers cGMP and cAMP. 18 ATG16L2 shares sequence homology with ATG16, a protein required for autophagy in yeast. 19 FCHSD2 is named for its FCH and SH3 protein domains. 20 Here, we show data supporting rs11603334 as a functional variant regulating ARAP1 expression. Dense fine-mapping data and conditional analyses support a single association signal. We demonstrate that the T2D-risk allele (C) of rs11603334 is associated with increased ARAP1 transcript levels in primary human pancreatic islets, disrupts binding of a protein complex containing transcriptional regulators, and increases transcriptional activity at the ARAP1 P1 promoter. These data suggest that increased ARAP1 P1 promoter activity and ARAP1 expression might be molecular consequences of the T2D-associated variants in this region.
Material and Methods

Study Population and Phenotypes
In the proinsulin association analyses, we included 8,635 Finnish men without diabetes and not taking diabetes medication ( ]; fasting plasma glucose levels < 7 mmol/l; and plasma glucose levels after 2 hr oral glucose tolerance test < 11.1 mmol/l) from the populationbased Metabolic Syndrome in Men (METSIM) study. 21 Fasting plasma-specific proinsulin (Human Proinsulin RIA Kit, Linco Research; no cross-reaction with insulin or C-peptide) and fasting insulin (ADVIA Centaur Insulin IRI, 02230141, Siemens Medical Solutions Diagnostics; minimal cross-reaction with proinsulin or C-peptide) were measured by immunoassay. For the T2D association analyses, 1,389 T2D cases and 5,748 normoglycemic controls were included. The study was approved by the ethics committee of the University of Kuopio and Kuopio University Hospital, and informed consent was obtained from all study participants.
Genotyping
Samples were genotyped with the Illumina HumanOmniExpress BeadChip. In sum, 681,789 autosomal SNPs passed quality control (Hardy-Weinberg equilibrium [HWE] p R 1 3 10 À6 in the total sample; call frequency R 0.97). The same samples were previously genotyped with the Illumina HumanExome BeadChip, 11 which focuses on protein-altering variants selected from >12,000 exome and genome sequences.
Imputation and Reference Panel
We used a two-step imputation strategy wherein samples were prephased with ShapeIT version 2 22 before genotypes were imputed with Minimac. 23 To increase imputation quality, we used 5,474 haplotypes from the 2,737 central-northern European samples sequenced within the Genetics of Type 2 Diabetes (GoT2D) study as a reference panel (C.F., J. Flannick, K. Gaulton, H. Kang, and the GoT2D Consortium, unpublished data).
Fine-Mapping and Conditional Analysis
Assuming an additive genetic model and adjusting for age, BMI, and log-transformed fasting plasma insulin, we tested SNP associations with log-transformed fasting plasma proinsulin levels by using a linear mixed model with an empirical kinship matrix to account for relatedness as implemented in EMMAX. 24 We analyzed both raw residuals and rank-based inverse-normal-transformed residuals to assess robustness of rare-variant associations with outliers. Genotyped variants with minor allele count R 5 (minor allele frequency [MAF]~0.03%) and HWE p R 1 3 10 À6 and imputed var-iants with imputation quality score R 2 > 0.3 and MAF R 0.03% were included in the analyses. To identify additional independent signals in the region, we performed conditional analyses on previously reported lead SNP rs11603334 or on our fine-mapped lead SNP rs7109575 by using allele count (genotyped variants) or allelic dosage (imputed variants) as a covariate in the model. SNP associations with T2D were tested similarly but with adjustment for age only. Kang et al. 24 describe and motivate the use of a linear mixed model for analysis of a binary outcome.
Allelic Expression Imbalance
Human islets from nondiabetic organ donors were obtained from the National Disease Research Interchange and the Islet Cell Resource Center Integrated Islet Distribution Program. DNA and RNA were obtained from 87 primary human pancreatic islet samples with the use of the PureGene (DNA) or RNAeasy (RNA) kits (QIAGEN). Reverse transcription of the RNA was performed with the Superscript III First-Strand Synthesis System (Life Technologies). Common, transcribed SNPs (MAF R 0.1) with the highest LD values with previously reported lead SNPs rs11603334 and rs1552224 were selected for testing allelic expression of ARAP1, STARD10, PDE2A, and FCHSD2. LD plots including the transcribed SNPs were created with the use of the HapMap Genome Browser ( Figure S1 , available online). 25 High-quality genomic DNA (gDNA) and mRNA were available for five islet samples heterozygous for rs11603334 and rs1552224; one additional high-quality heterozygous sample each was available for mRNA only or gDNA only. For each transcribed SNP, the relative proportions of each allele comprising the gDNA and cDNA were quantified with Sequenom iPLEX MALDI-TOF mass-spectrometry-based genotyping (Sequenom). Primers were designed with MassARRAY (Sequenom) ( Table S1 ). We designed primers within a single exon to avoid amplicon size differences between gDNA and cDNA, except for rs2291289, which is located near an exon-intron boundary. To control for assay variation, we analyzed the proportions of each SNP allele measured in the cDNA relative to measurements taken in the gDNA. Data are reported as the percentage of total gDNA or cDNA containing a given transcribed SNP allele. The statistical significance of the differences in allelic representation was determined on the basis of LD scenarios as previously described. 26 In brief, two-sided t tests were used when the transcribed SNP and lead SNPs were in perfect LD (D 0 ¼ 1.0, r 2 ¼ 1.0) or when the transcribed SNP and lead SNPs were in intermediate LD with low pairwise correlation (D 0 z 1.0, r 2 < 0.2). For all t tests, F tests were first used for determining equal or unequal variance. Nonparametric Wilcoxon pairwise tests were used instead of t tests when gDNA or cDNA measurement data were not normally distributed. One-sided F tests were used when the transcribed SNP and lead SNPs were in low LD (D 0 < 0.2, r 2 < 0.2).
Regulatory Variant Selection
All known variants in high LD (r 2 R 0.8, EUR) with rs11603334 and rs1552224 were identified with the use of Phase 1 data from the 1000 Genomes Project. 27 Variants were prioritized on the basis of location relative to regions of potential regulatory function, as indicated by the following: open chromatin in primary human pancreatic islets detected by FAIRE 28 and DNase hypersensitivity, 29 accessible chromatin in primary human pancreatic islets detected by chromatin immunoprecipitation sequencing (ChIP-seq) of active histone H3 lysine methylation or acetylation modifications (H3K4me3, H3K4me1, and H3K9ac) as reported in the Human Epigenome Atlas, 30 and transcription factor binding in ENCODE tissues or cell lines detected by ChIP-seq. 31 
Cell Culture
The MIN6 mouse insulinoma beta cell line 32 was grown in Dulbecco's modified Eagle's medium (Sigma) supplemented with 10% fetal bovine serum (FBS), 1 mM sodium pyruvate, and 100 mM 2-mercaptoethanol. The INS-1-derived 832/13 rat insulinoma beta cell line 33 (a gift from C.B. Newgard, Duke University) was grown in RPMI 1640 culture medium (Corning Cellgro) supplemented with 10% FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, 10 mM HEPES, and 0.05 mM 2-mercaptoethanol. Both lines were maintained at 37 C and 5% CO 2 . One day prior to transfection, MIN6 cells were seeded at a density of 200,000 cells per well on 24-well plates. 832/13 cells were seeded at a density of 300,000 cells per well on 24-well plates or 150,000 cells per well on 48-well plates.
Dual Luciferase Transcriptional Reporter Assay
Genomic regions including variant positions were PCR amplified from human gDNA with 5 PRIME Mastermix (5 PRIME) or the Expand High Fidelity PCR System (Roche) with the primers listed in Table S2 . Amplified DNA was subcloned with restriction enzymes XhoI, KpnI, and/or NheI and T4 DNA Ligase (New England Biolabs) into the multiple cloning site upstream of the firefly luciferase gene in the pGL4.10 promoterless vector (Promega). Site-directed mutagenesis was performed with the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent) and the primers listed in Table S2 . For each construct, two to ten independent clones were selected. The fidelity and genotype of each gDNA construct were verified by sequencing. Equal amounts, between 600 and 800 ng, of each gDNA construct or empty pGL4.10 promoterless vector were cotransfected with 80 ng of Renilla luciferase vector into duplicate wells of MIN6 or 832/13 cells with Lipofectamine 2000 (Life Technologies). Transfected cells were incubated at 37 C and 5% CO 2 overnight, and the transfection media were replaced with fresh culture media after 24 hr. Forty-eight hours posttransfection, cell lysates were collected and assayed for luciferase activity with the Dual-Luciferase Reporter Assay System (Promega). We normalized firefly luciferase activity to that of Renilla luciferase to control for differences in transfection efficiency. Normalized data are reported as the fold change (5SD) in activity relative to that of the empty pGL4.10 promoterless vector control. Two-sided Student's t tests were used for comparing luciferase activity between genotypes or haplotypes. F tests were used for determining equal or unequal variance. Two-way ANOVA was used for simultaneous comparisons of haplotypes resulting from two independently tested SNPs.
Electrophoretic Mobility Shift Assay and Transcription Factor Prediction
Four sets of complementary 21-mer oligonucleotides centered on rs11603334 (C/T) or rs1552224 (T/G) were generated; each contained either of the two alternate alleles, both with and without biotin end labeling (Integrated DNA Technologies). We annealed each set to create double-stranded oligonucleotides by incubating 50 pmol of each single-stranded oligonucleotide in buffer containing 10 mM Tris, 1 mM EDTA, and 50 mM NaCl at 95 C for 5 min and then gradually cooled them to 4 C. Double-stranded oligonu-cleotide sequences are specified in Table S3 . Nuclear protein lysates were extracted from MIN6 and 832/13 cell pellets with NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific), and protein concentrations were determined with the Pierce BCA Protein Assay (Thermo Scientific). Electrophoretic mobility shift assays (EMSAs) were carried out with the LightShift Chemiluminescent EMSA Kit (Thermo Scientific) according to the manufacturer's instructions. Each protein-DNA binding reaction contained 13 binding buffer, 1 mg poly(dIdC), 4 mg nuclear protein lysates, and 100 fmol biotin-labeled double-stranded oligonucleotide in 20 ml total reaction volume. For reactions demonstrating DNA competition, 60-fold excess unlabeled double-stranded oligonucleotide was preincubated with nuclear protein lysates in the reaction mixture for 20 min before the addition of biotin-labeled oligonucleotide. For EMSA reactions with supershift, 4 mg antibody was added to the final reaction mixture and the samples were incubated for an additional 30 min. We used JASPAR, 34 TRANSFAC, 35 CONSITE, 36 PWMSCAN, 37 and Tfsitescan 38 to computationally predict transcription factors that might differentially bind at rs11603334 by contrasting the predictions and/or scores generated for each SNP allele. Transcription factor ChIP-seq data for the region overlapping rs11603334 were obtained from the ENCODE project. 31 Antibody to PAX6 (PRB-278P) was purchased from Covance. Antibodies to PAX4 (M-45X, sc-98942X) and AP-2b (H-87X, sc-8976X) were purchased from Santa Cruz Biotechnology. Antibodies to HIF1a (MA1-516) and HIF1b (MA1-515) were purchased from Thermo Scientific. Additional antibodies to the following factors were also purchased and tested for supershift: YY1 (39071, 39345), Active Motif; NFIC (ab86570), Abcam; and AP-2a
, CEBPb (C-19, sc-150X), CUX1 (C-20, sc-6327X), and p300 (C-20, sc-585X), Santa Cruz Biotechnology. Protein-DNA complexes were separated by electrophoresis on 6% DNA retardation gels (Life Technologies) in 0.5 X TBE (Lonza), transferred to nylon membranes (Thermo Scientific), and UV crosslinked before chemiluminescent detection.
Results
Fine Mapping of the 11q13.4 Locus, Associated with Fasting Proinsulin and T2D To fine map the association signal for fasting proinsulin, we performed association analyses in 8,635 Finnish subjects from the METSIM study with SNPs imputed from a reference panel of 2,737 sequenced central-northern European individuals and SNPs directly genotyped on an exome array. 11 The lead SNP was rs7109575 (p ¼ 7.4 3 10 À50 ; n ¼ 8,635), a noncoding variant located at the ARAP1 P2 TSS ( Figure 1 and Table S4 ) and in high LD (r 2 ¼ 0.94) with previously reported lead proinsulin-associated SNP rs11603334 10 (p ¼ 2.2 3 10 À48 ; n ¼ 8,630). Conditional analyses using rs11603334 or rs7109575 as covariates largely attenuated the proinsulin association signal (all SNPs, p > 1.0 3 10 À5 ; Figure 1 , Figure S2 , Table S4 , and data not shown). One rare missense variant genotyped in a 1 Mb region on the exome array was associated (p < 0.05) with proinsulin after conditional analysis (rs202137453, Table S4 ). T2D association using 1,389 case and 5,748 control subjects (rs7109575, p ¼ 2.2 3 10 À3 ; rs11603334, p ¼ 3.6 3 10 À3 ) was also attenuated after conditional analysis (p > 0.05; Table S4 , Figure S3 , and data not shown). Taken together, fine-mapping and conditional analyses provide evidence supporting a functional role for common variant(s) in high LD with rs7109575 and rs11603334.
The Proinsulin-Decreasing and T2D-Risk Alleles Are Associated with Increased ARAP1 mRNA Levels in Primary Human Pancreatic Islets To determine whether expression of ARAP1, STARD10, PDE2A, or FCHSD2 is associated with the T2D-and fasting-proinsulin-associated lead SNPs, we evaluated allelic expression imbalance (AEI) in primary human pancreatic islets. AEI maximizes sensitivity and power to detect modest cis-acting effects on mRNA expression through quantification of allele-specific transcript levels within heterozygous samples, thereby controlling for differential trans-acting and environmental exposures between individuals, 40 as well as differential sample purity and viability between islet preparations. 41, 42 The allelic composition of the total transcript level for each gene was quantitatively determined with Sequenom MALDI-TOF mass spectrometry, a sensitive approach that conserves limited biological sample, and statistically analyzed relative to the allelic composition of the gDNA (Material and Methods). Located in the first exon and 5 0 UTR of ARAP1 isoforms transcribed Each SNP is colored according to its LD (r 2 ) with rs11603334. Genomic coordinates refer to hg18 (UCSC Genome Browser). from P1, previously reported lead SNPs rs11603334 and rs1552224 demonstrated AEI (Figure 2 ). In six samples heterozygous for rs11603334 and rs1552224, we observed ARAP1 expression differences of 7%-12% between alleles. For both SNPs, the T2D-risk alleles were associated with higher ARAP1 transcript levels (rs11603334, p ¼ 0.0002; rs1552224, p ¼ 0.015). Because of lower LD between the lead SNPs and a third ARAP1 transcribed SNP located in a downstream exon, rs2291289 (r 2 ¼ 0.12, D 0 ¼ 1.0, rs11603334, EUR), only three samples were heterozygous for both rs2291289 and rs11603334 ( Table 1 ). The gDNA-to-cDNA comparison showed no AEI, whereas a comparison among cDNA samples showed the nonrisk allele associated with modestly increased transcript levels ( Figure S4A ). We also attempted to evaluate AEI for nearby genes containing transcribed SNPs in lower LD with rs11603334 by applying previously described statistical methods. 26 We did not observe significant evidence of AEI for STARD10, PDE2A, or FCHSD2 ( Figures S4B-S4D and data not shown); zero to four samples were heterozygous for each transcribed SNP and rs11603334 (Table 1) . Overall, these results suggest that one or more functional variants in high LD with rs11603334 and rs1552224 could increase the transcriptional activity or message stability of ARAP1 isoforms containing these SNPs.
Candidate Regulatory Variants at the ARAP1 Promoters
The originally identified lead SNPs rs11603334 and rs1552224 at the P1 promoter overlap ENCODE transcription factor binding sites within a region of open and accessible chromatin that is marked by DNase hypersensitivity and active histone H3 lysine modifications H3K4me3 and H3K9ac in human pancreatic islets ( Figure 3 and Table S5 ). The lead fine-mapped SNP in this study, rs7109575 (r 2 ¼ 0.94 with rs11603334, EUR), is located within a region of islet DNase hypersensitivity and clustered transcription factor binding at the P2 promoter ( Figure S5 and Table S5 ). Among the 17 additional variants in high LD with rs11603334 (r 2 R 0.8, EUR; Table S5 ), rs77464186 (r 2 ¼ 0.95 with rs11603334, EUR) is the next most promising functional candidate because of its location within a region of islet DNase hypersensitivity and clustered transcription factor binding in the first intron of ARAP1 isoforms transcribed from the P2 promoter ( Figure S5 and Table S5 ).
The rs11603334 T2D-Risk and Proinsulin-Decreasing Allele Increases Transcriptional Reporter Activity in Rodent Pancreatic Beta Cell Lines To interrogate allelic differences in transcriptional activity of rs11603334, rs1552224, rs7109575, and rs77464186, we cloned DNA sequences containing the T2D-risk (proinsulin-decreasing) or nonrisk (proinsulin-increasing) alleles into a promoterless luciferase vector and measured luciferase activity in the MIN6 mouse and 832/13 rat beta cell lines. Because of the perfect LD and short distance between rs1552224 and rs11603334, we first tested them together as a haplotype in the context of the ARAP1 P1 promoter. A 1,357 bp region of DNA, defined by DNase hypersensitivity in human pancreatic islets and Pol2 binding in several other cell types (Figure 3) , exhibited strong transcriptional activity in comparison to an empty vector control in both MIN6 ( Figure 4A ) and 832/13 ( Figure 4B) . The rs1552224 and rs11603334 T2D-risk haplotype (TC) demonstrated a 2-fold increase in transcriptional activity in comparison to the nonrisk haplotype (GT) in both MIN6 (p < 0.0001) and 832/13 (p ¼ 0.015), consistent with our finding that the T2D-risk alleles are associated with increased ARAP1 expression. The 1,357 bp region also contained two short sequences of variable CT repeat length (CT 6-10 ); however, the numbers of repeats at the two sites did not influence transcriptional activity ( Figures S6A  and S6B) . A narrower, 245 bp DNA region (Figure 3 ) containing only variants rs1552224 and rs11603334 also exhibited strong transcriptional activity in comparison to an empty vector control ( Figure 4C ). As observed with the 1,357 bp region, the two-SNP T2D-risk haplotype (TC) demonstrated a 2-fold increase in transcriptional activity in comparison to the nonrisk haplotype (GT) (p ¼ 0.012). To determine which of the SNPs was responsible for the haplotype effects on transcriptional activity at the P1 promoter, we used site-directed mutagenesis to synthetically create the alternate ''missing'' haplotypes. Compared to the nonrisk T allele, the T2D-risk allele (C) Figure 2 . The T2D-Risk Alleles of rs11603334 and rs1552224 Are Associated with Increased ARAP1 Expression Allelic expression analysis in human pancreatic islet gDNA and cDNA from six donors each, including five matched pairs (matched pairs only: rs11603334, p ¼ 0.0008; rs1552224, p ¼ 0.06). The proportion of total gDNA and cDNA containing the T2D-risk alleles of rs11603334 (left) and rs1552224 (right) from heterozygous samples are quantified on the y axis. The cDNA containing the T2D-risk allele was expressed 12.6% and 7.3% more than the cDNA containing the nonrisk allele in the rs11603334 and rs1552224 assays, respectively. The p values were calculated with a two-sided t test. of rs11603334 replicated the previously observed 2-fold increase in transcriptional activity (p < 0.0001), whereas the T2D-risk and nonrisk alleles of rs1552224 (T/G) showed no significant difference ( Figure 4D ). We did not observe evidence of allelic differences in transcriptional activity for either rs7109575 ( Figure 4E ) or rs77464186 ( Figure S6C ) near the P2 promoter. However, compared to the empty control vector, the 287 bp region of DNA surrounding rs7109575 increased transcriptional activity 9-fold (p < 0.0001), consistent with promoter activity.
Decreased In Vitro Binding of PAX6 and PAX4 to the rs11603334 T2D-Risk and Proinsulin-Decreasing Allele
We performed EMSAs by using nuclear protein lysates extracted from MIN6 and 832/13 cell lines to evaluate differences in transcription factor binding to alleles of rs11603334 and rs1552224. Multiple protein-DNA complexes were observed in the EMSAs, consistent with expectations for DNA within a promoter region ( Figure 5 and Figure S7 ). At least one protein complex was observed to bind specifically to the nonrisk (T) allele of rs11603334 in MIN6 ( Figure 5A, arrow) . DNA competition assays using excess unlabeled oligonucleotide containing the T allele reproducibly disrupted the protein-DNA complex more efficiently than did excess unlabeled oligonucleotide containing the C allele, further supporting allelic differences in protein binding ( Figure 5A Figure 5B, lane 10) . Among the other transcription factors tested with supershift assay, only AP-2b, HIF1a, and HIF1b were observed to bind to the 21 bp DNA sequence containing rs11603334; these proteins bound to both the C and T alleles with approximately equal affinity ( Figures S7B  and S7C, arrows) . We did not observe clear evidence of allele-specific protein binding to rs1552224 ( Figure S7D ).
Discussion
For most T2D-associated loci identified through GWASs, the functional variants and affected genes are not known. In this study, we have identified a plausible functional regulatory variant, rs11603334, and demonstrated its allelic effects on expression of ARAP1, a gene at the 11q13.4 Table S5 ). The DNA sequences cloned for evaluating differential allelic transcriptional activity in the dual-luciferase reporter assays are indicated.
locus. We provide evidence suggesting that the C allele of rs11603334 disrupts binding of transcriptional regulators and increases transcriptional activity at the ARAP1 P1 promoter and thus leads to higher ARAP1 expression in pancreatic islets. Increased ARAP1 expression might be one molecular genetic contributor to T2D susceptibility. We conducted association analyses by using the densest set of variants to date and report rs7109575 as the lead fine-mapped SNP, confirming the primary robust association between fasting proinsulin and previously reported lead SNPs rs11603334 and rs1552224. Although not the most strongly associated SNP in this study, our proposed functional SNP (rs11603334) had an association p value (p ¼ 2.2 3 10 À48 ) similar to that of rs7109575 (p ¼ 7.4 3 10 À50 ); sampling variability, missing genotypes, or imputation uncertainty might influence the relative p values. Conditioning on either rs11603334 or rs7109575 attenuated the proinsulin association, consistent with a single signal at this locus and supporting the use of the r 2 measure of LD for identifying candidate functional SNPs. Rare variants might also contribute to variation in proinsulin levels among carriers. The variant that became more significant after adjustment for rs11603334 (rs202137453, STARD10 c.586C>T [p.Pro196Ser]) might be a true signal or a false positive among 3,818 variants tested in this region. Further finemapping and conditional analyses using a larger T2D casecontrol population will be needed for determining whether other variants in the region also contribute to T2D risk.
We have demonstrated that the T2D-risk alleles of rs11603334 and rs1552224 are associated with increased ARAP1 mRNA expression in primary human pancreatic islets. This finding was reproducibly evident with a small number of samples because AEI compares quantification of allele-specific mRNA levels within heterozygous individuals and thereby minimizes confounding effects, such as interindividual environmental exposures, that can mask genotypic effects in studies of expression quantitative trait loci (eQTLs). We had the best power to detect association between ARAP1 mRNA expression and rs11603334 and rs1552224 because the SNPs are located within an exon; this exon is specific to ARAP1 isoforms transcribed from the P1 promoter. Previously, rs519790 was reported to be a strong eQTL for STARD10 in blood (p ¼ 2.7 3 10 À24 ); 1 however, this SNP is in low LD with rs1552224 (r 2 ¼ 0.071, EUR), which shows only a modest, residual eQTL association with STARD10 (blood, p ¼ 8.6 3 10 À7 ; liver, p ¼ 1.79 3 10 À5 ; omental adipose tissue, p ¼ 1.21 3 10 À6 ). 43 A nominal association between rs1552224 and ARAP1 (CENTD2) expression has been previously reported in T cells (p ¼ 0.019) in a direction consistent with our results. 44, 45 In agreement with our finding that the T2D-risk alleles of rs11603334 and rs1552224 are associated with increased ARAP1 expression, our experiments using the transcriptional reporter assay showed that the T2D-risk allele of rs11603334 upregulates transcriptional activity at the ARAP1 P1 promoter. Although transcriptional activity at a gene promoter might be expected, allelic differences in promoter activity cannot be predicted easily; functional assays are necessary for demonstrating allelic effects. Among three tested variants situated at the ARAP1 P1 and P2 promoters in this study, only rs11603334 demonstrated allelic effects on promoter activity. Taken together, the results from the AEI and transcriptional reporter assays implicate increased expression of ARAP1 isoforms containing rs11603334 and transcribed from the P1 promoter (RefSeq accession numbers NM_015242.4 and NM_001135190.1) in T2D susceptibility.
We have shown that the beta cell transcriptional regulator PAX6 preferentially binds to the mRNA-lowering allele (T) of rs11603334 in a protein-DNA complex that could also contain PAX4, suggesting a repressive role for one or both factors in transcription at the ARAP1 P1 promoter ( Figure 6 ). PAX6 and PAX4 have similar binding sequences, although they bind DNA with different relative affinities. [46] [47] [48] In the endocrine pancreas, PAX6 is often reported to function as a transcriptional activator, whereas PAX4 often functions as a repressor. PAX4 has been shown to inhibit the transcriptional activity of coexpressed PAX6 in the HIT-T15 hamster beta cell line and in 293T cells, possibly through competition for DNA binding sites. 47 PAX4 also represses basal transcriptional activity of the glucagon promoter in aTC1.9 and InR1G9 cells and strongly represses PAX6-activated transcription of both the glucagon 48 and insulin promoters. 49 However, repressive activity for human and mouse PAX6 has also been demonstrated for specific regulatory elements in other cell types. [50] [51] [52] The observed inhibition of transcriptional activity for ARAP1 transcripts containing the rs11603334 T allele might be mediated by PAX4, PAX6, or both. Human coding variants in PAX4 or PAX6 have been previously implicated in impaired glucose tolerance, 53, 54 early-onset diabetes, 53, 55 ketosis-prone diabetes, 56 and proinsulin processing. 57 Recently, genomewide association signals for T2D have also been identified near PAX4 in East Asian 2 and Chinese populations. 58 Our results do not preclude the existence of additional functional genes, variants, and/or mechanisms at this locus. Power to detect association between the lead SNPs and expression levels of STARD10, PDE2A, and FCHSD2 was limited as a result of small numbers of SNPs and samples informative for AEI. Although 87 total islet samples were available, only six were heterozygous for rs11603334 and zero to four samples were informative for the STARD10, PDE2A, and FCHSD2 assays. We cannot exclude possible associations between rs11603334 and expression levels of these genes. An assay to test AEI for all isoforms of ARAP1 (with the use of rs2291289) similarly was of limited utility because of the small number of heterozygous samples (n ¼ 3) for this SNP and wide assay variance. Moreover, ATG16L2 could not be tested with this approach because it does not contain any common transcribed SNPs. Future analysis of a larger pancreatic islet expression data set will be required for validating our findings for ARAP1 and assessing allelic differences in gene expression for all other genes.
We chose to investigate the mechanisms underlying the set of variants most strongly associated with proinsulin and T2D after dense fine-mapping analyses. We prioritized among highly significant noncoding variants on the basis of their locations within regions of open chromatin in pancreatic islets and successfully identified a variant with allelic differences in transcriptional activity. Variants located outside of these open chromatin regions might also be found to have regulatory function. In addition, functional noncoding variants at this locus might regulate gene expression through allelic effects on splicing, message stability, or translational control. On the basis of sequence, rs1552224 creates a possible splice site, and the rs11603334 T allele creates a methionine codon upstream of the RefSeq start codon. If used, this codon could potentially lead to attempted translation of a 90 nt upstream open reading frame, which could interfere with efficient translation of ARAP1. 59 Specific roles for ARAP1 in the process of proinsulin conversion and/or insulin secretion in the beta cell have not yet been reported. ARAP1 is located near both the Golgi and the plasma membrane in other cell types 16, [60] [61] [62] and has been demonstrated to regulate several members of the Arf and Rho small GTPase protein families in vitro and in cell culture. 16, 63 Of the reported substrates, both ARF6 and CDC42 have been shown to play a role in glucose-stimulated insulin secretion. [64] [65] [66] Future work will address the effects of upregulated ARAP1 expression on proinsulin processing and insulin secretion in the pancreatic beta cell. Given that our data suggest that increased ARAP1 expression is associated with increased risk of T2D, ARAP1 antagonists might hold important therapeutic potential.
Identifying functional variants at T2D GWAS loci and elucidating mechanisms to explain how variants influence expression or function of target genes will help facilitate the discovery of biological gene candidates and novel pathways involved in disease pathology. This work contributes to a growing understanding of the molecular genetic architecture of T2D, provides a model of finemapping and experimental analyses that can be used for uncovering functional variants contributing to associations at GWAS loci, and paves the way for future research on the role of ARAP1 as a diabetes candidate gene in pancreatic islets.
Supplemental Data
Supplemental Data include seven figures and five tables and can be found with this article online at http://www.cell.com/AJHG. Figure 6 . Proposed Model for PAX6 and PAX4 Repression of Transcriptional Activity at ARAP1 PAX6 and PAX4 at rs11603334 in a complex with stronger binding to the ARAP1 mRNA-decreasing T allele (B, T2D nonrisk) than to the mRNA-increasing C allele (A, T2D risk) suggests a role for one or both of these factors in repressing transcription at the ARAP1 P1 promoter. Transcription factors HIF1a, HIF1b, and AP-2b bind both alleles.
